Table 2. Concentrations (relative unit) of metabolites at healthy state, their concentration fold changes and their corresponding satisfaction grades of the adverse effect in VM50 and various treatments by current prescription drugs.
| Concentration | Fold change (ηj(xj)) | ||||||
|---|---|---|---|---|---|---|---|
| Metabolite | HS | VM50/HS | L-DOPA/HS | DA-AG/HS | COMT/HS | MAOI/HS | Status |
| DA-e, x9 | 400 | 0.486(0.43) | 0.673 (0.636) | 0.806 (0.784) | 0.735 (0.756) | 1.0 (1.0) | Therapeutic |
| DOPA-Q, x5 | 5 | 1.512 (0.943) | 7.962 (0.226) | 5.429 (0.508) | 3.192 (1.0) | 2.634 (0.818) | Toxic |
| 3-MT, x10 | 20 | 1.101 (0.989) | 1.057 (0.994) | 1.032 (0.996) | 0.1 (1.0) | 1.035 (0.996) | Toxic |
| DOPAL-e, x11 | 10 | 0.241 (1.0) | 0.457 (1.0) | 0.653 (1.0) | 0.262 (1.0) | 0.706 (1.0) | Toxic |
| DA-Q, x16 | 10 | 1.548 (0.939) | 4.413 (0.621) | 6.953 (0.339) | 3.593 (0.712) | 2.801 (0.8) | Toxic |
| DOPAL, x24 | 5 | 1.095 (0.989) | 1.271 (0.97) | 1.463 (0.949) | 1.294 (0.967) | 0.738 (1.0) | Toxic |
| DOPAC-Q, x26 | 10 | 1.127 (0.986) | 1.446 (0.95) | 1.672 (0.925) | 1.41 (0.954) | 0.757 (1.0) | Toxic |
| O2−, x27 | 5 | 1.182 (0.98) | 1.857 (0.905) | 2.042 (0.884) | 1.613 (0.932) | 0.921 (1.0) | ROS |
| H2O2, x28 | 5 | 1.13 (0.986) | 1.543 (0.94) | 1.694 (0.923) | 1.422 (0.953) | 0.872 (1.0) | ROS |
| H2O2-e, x29 | 2 | 0.763 (1.0) | 0.854 (1.0) | 0.915 (1.0) | 0.344 (1.0) | 0.97 (1.0) | ROS |
| HO, x30 | 2 | 1.287 (0.968) | 2.471 (0.837) | 3.001 (0.778) | 2.074 (0.881) | 0.758 (1.0) | ROS |
| HO-NO2, x31 | 2 | 1.24 (0.973) | 2.301 (0.855) | 2.553 (0.827) | 1.862 (0.904) | 0.961 (1.0) | RNS |
| NO2, x32 | 2 | 1.144 (0.984) | 1.77 (0.914) | 1.902 (0.9) | 1.508 (0.943) | 1.002 (1.0) | RNS |
HS and VM50 denote as the healthy state and 50% VMAT2 deficiency, respectively. L-DOPA/HS, DA-AG/HS, COMT/HS and MAOI/HS are the concentration fold changes for treating L-DOPA, dopamine agonist, MAOI, and COMT inhibitors, respectively. ηj(xj) in parentheses is the corresponding satisfaction grade of the adverse effect.